Transduced PEP-1-FK506BP ameliorates corneal injury in Botulinum toxin A-induced dry eye mouse model

BMB Reports

Volumn 46, Issue 2, 2013, Pages 124-129

  Kim, Dae Won ^a   Lee, Sung Ho ^b   Ku, Sae Kwang ^c   Cho, Soo Hyun ^c   Cho, Sung Woo ^d   Yoon, Ga Hyeon ^a   Hwang, Hyun Sook ^a   Park, Jinseu ^a   Eum, Won Sik ^a   Kwon, Oh Shin ^e   Choi, Soo Young ^a  

^a Hallym University   (South Korea)

^b Lumieye Genetics Co Ltd   (South Korea)

^c Daegu Haany University   (South Korea)

^d University of Ulsan College of Medicine   (South Korea)

^e Kyungpook National University   (South Korea)

Author keywords

Cytokines; Dry eye disease; Inflammation; PEP 1 FK506BP; Protein therapy

Indexed keywords

BOTULINUM TOXIN A; DRUG DERIVATIVE; FK 506 BINDING PROTEIN; HYBRID PROTEIN; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN; MERCAPTAMINE; PEP 1 PEPTIDE; PEP-1 PEPTIDE; PEPTIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL LINE; CHEMICALLY INDUCED DISORDER; CONJUNCTIVA; CORNEA; DISEASE MODEL; DRUG EFFECT; DRY EYE; GENETIC TRANSDUCTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MOUSE; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANIMALS; BOTULINUM TOXINS, TYPE A; CELL LINE; CONJUNCTIVA; CORNEA; CYSTEAMINE; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-1BETA; MACROPHAGE INFLAMMATORY PROTEINS; MICE; PEPTIDES; RECOMBINANT FUSION PROTEINS; TACROLIMUS BINDING PROTEINS; TRANSDUCTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84874685452     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2013.46.2.272     Document Type: Article

References (35)

1. Schaumberg, D. A., Sullivan, D. A., Buring, J. E. and Dana, M. R. (2003) Prevalence of dry eye syndrome among US women. Am. J. Ophthalmol. 136, 318-326.
2. Schaumberg, D. A., Sullivan, D. A. and Dana, M. R. (2002) Epidemiology of dry eye syndrome. Ade. Exp. Med. Biol. 506, 989-998.
3. Behrens, A., Doyle, J. J., Stern, L., Chuck, R. S., Mcdonnell, P. J., Azar, D. T., Dua, H. S., Hom, M., Karpecki, P. M., Laibson, P. R., Lemp, M. A., Meisler, D. M., Del Castillo, J. M., O'Brien, T. P., Pflugfelder, S. C., Rolando, M., Schein, O. D., Seitz, B., Tseng, S. C., van Setten, G., Wilson, S. E. and Yiu, S. C. (2006) Dysfunctional tear syndrome study group. Dysfunctional tear syndrome: a Delphi approach to treatment recommendations. Cornea 25, 900-907.
4. Gupta, H., Jain, S., Mathur, R., Mishra, P., Mishra, A. K. and Velpandian, T. (2007) Sustained ocular drug delivery from a temperature and pH triggered novel in situ gel system. Drug Deliv. 14, 507-515.
5. Khaw, P. T., Shah, P. and Elkington, A. R. (2004) Injury to the eye. BMJ 328, 36-38.
6. Hosseini, H. and Nejabat, M. (2007) A potential therapeutic strategy for inhibition of corneal neovascularization with new anti-VEGF agents. Med. Hypotheses 68, 799-801.
7. Schaumberg, D. A., Buring, J. E., Sullivan, D. A. and Dana, M. R. (2001) Hormone replacement therapy and dry eye syndrome. JAMA 286, 2114-2119.
8. Narayanan, S., Miller, W. L. and Mcdermott, A. M. (2006) Conjunctival cytokine expression in symptomatic moderate dry eye subjects. Invest. Ophthalmol. Vis. Sci. 47, 2445-2450.
9. Luo, L., Li, D.Q., Doshi, A., Farley, W., Corrales, R. M. and Pflugfelder, S. C. (2004) Experimental dry eye stimulates production of inflammatory cytokines and MMP-9 and activates MAPK signaling pathways on the ocular surface. Invest. Ophthalmol. Vis. Sci. 45, 4293-4301.
10. Dana, M. R. and Hamrah, P. (2002) Role of immunity and inflammation in corneal and ocular surface diseases associated with dry eye. Ade. Exp. Med. Biol. 506, 729-738.
11. Gulati, A., Sacchetti, M., Bonini, S. and Dana, R. (2006) Chemokine receptor CCR5 expression in conjunctival epithelium of patients with dry eye syndrome. Arch. Ophthalmol. 124, 710-716.
12. Solomon, A., Dursun, D., Liu, Z., Xie, Y., Macri A. and Pflugfelder, S. C. (2001) Pro- and anti-inflammatory forms of inerleukin-1 in the tear fluid and conjunctiva of patients with dry eye diseases. Invest. Ophthalmol. Vis. Sci. 42, 2283-2293.
13. Perry, H. D., Solomon, R., Donnenfeld, E. D., Perry, A. R., Wittpenn, J. R., Greenman, H. E. and Savage, H. E. (2008) Evaluation of topical cyclosporine for the treatment of dry eye diseases. Arch. Ophthalmol. 126, 1046-1050.
14. De Paiva, C. S., Corrales, R. M. and Villarrea, A. L. (2006) Corticosteroid and doxycycline suppress MMP-9 and inflammatory cytokine expression, MAPK activation in the corneal epithelium in experimental dry eye. Exp. Eye Res. 83, 526-535.
15. Li, N., He, J., Schwartz, C. E., Gjorstrup, P. and Bazan, H. E. (2010) Resolvin E1 improves tear production and decreases inflammation in a dry eye mouse model. J. Ocul. Pharmacol. Ther. 26, 431-439.
16. Hongyok, T., Chae, J. J., Shin, Y. J., Na, D., Li, L. and Chuck, R. S. (2009) Effect of chitosan-N-acetylcysteine conjugate in a mouse model of Botulium toxin B-induced dry eye. Arch. Ophthalmol. 127, 525-532.
17. Zhu, L., Shen, J., Zhang, C., Park, C. Y., Kohanim, S., Yew, M., Parker, J. S. and Chuck, R. S. (2009) Inflammatory cytokine expression on the ocular surface in the Botulium toxin B induced murine dry eye model. Mol. Vis. 15, 250-258.
18. Jiang, W., Cazacu, S., Xiang, C., Zenklusen, J. C., Fine, H. A., Berens, M., Armstrong, B., Brodie, C. and Mikkelsen, T. (2008) FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-κB signaling pathway. Neoplasis 10, 235-243.
19. Kim, S. Y., Jeong, H. J., Kim, D. W., Kim, M. J., An, J. J., Sohn, E. J., Kang, H. W., Shin, M. J., Ahn, E. H., Kwon, S. W., Kim, D. S., Cho, S. W., Park, J., Eum, W. S. and Choi, S. Y. (2011) Transduced PEP-1-FK506BP inhibits the inflammatory response in the Raw 264.7 cells and mouse models. Immunobiol. 216, 771-781.
20. Kim, S. Y., Sohn, E. J., Kim, D. W., Jeong, H. J., Kim, M. J., Kang, H. W., Shin, M. J., Ahn, E. H., Kwon, S. W., Kim, Y. N., Kwon, H. J., Kim, T. Y., Lee, K. S., Park, J., Eum, W. S. and Choi, S. Y. (2011) Transduced PEP-1-FK506BP ameliorates atopic dermatitis in NC/Nga mice. J. Invest. Dermatol. 131, 1477-1485.
21. Dietz, G. P. (2010) Cell-penetrating peptide technology to deliver chaperones and associated factors in diseases and basic research. Curr. Pharm. Biotechol. 11, 167-174.
22. Wadia, J. S. and Dowdy, S. F. (2002) Protein transduction technology. Curr. Opin. Biotechnol. 13, 52-56.
23. Ahn, E. H., Kim, D. W., Kang, H. W., Shin, M. J., Won, M. H., Kim, J., Kim, D. S., Kwon, O. S., Kang, T. C., Han, K. H., Park, J., Eum, W. S. and Choi, S. Y. (2010) Transduced PEP-1-ribosomal protein S3 (rpS3) ameliorates 12-O-tetradecanoyl phorbol-13-acetate-induced inflammation in mice. Toxicol. 276, 192-197.
24. Shin, M. J., Lee, Y. P., Kim, D. W., An, J. J., Jang, S. H., Cho, S. M., Sheen, S. H., Lee, H. R., Kweon, H. Y., Kang, S. W., Lee, K. G., Park, J., Eum, W. S., Cho, Y. J. and Choi, S. Y. (2010) Transduced PEP-1-AMPK inhibits LPS-induced COX-2 and iNOS expression in Raw264.7 cells. BMB Rep. 43, 40-45.
25. Eum, W. S., Kim, D. W., Hwang, I. K., Yoo, K. Y., Kang, T. C., Jang, S. H., Choi, H. S., Choi, S. H., Kim, Y. H., Kim, S. Y., Kwon, H. Y., Kang, J. H., Kwon, O. S., Cho, S. W., Lee, K. S., Park, J., Won, M. H. and Choi, S. Y. (2004) In vivo protein transduction: Biologically active intact PEP-1-superoxide dismutase fusion protein efficiently protects against ischemic insult. Free Radic. Biol. Med. 37, 1656-1669.
26. Kwon, S. W., Sohn, E. J., Kim, D. W., Jeong, H. J., Kim, M. J., Ahn, E. H., Kim, Y. N., Dutta, S., Kim, D. S., Park, J., Eum, W. S., Hwang, H. S. and Choi, S. Y. (2011) Anti-inflammatory effect of transduced PEP-1-heme oxygenase-1 in Raw 264.7 cells and a mouse edema model. Biochem. Biophys. Res. Commun. 411, 354-359.
27. Lim, K. S., Won, Y. W., Park, Y. S. and Kim, Y. H. (2010) Preparation and functional analysis of recombinant protein transduction domain-metallothionein fusion proteins. Biochimie 92, 964-970.
28. Wang, H., Zhong, C. Y., Wu, J. F., Huang, Y. B. and Liu, C. B. (2010) Enhancement of TAT cell membrane penetration efficiency by dimethyl sulphoxide. J. Con. Rel. 143, 64-70.
29. Liu, X., Lin, Z., Zhou, T., Zong, R., He, H., Liu, Z., Ma, J. X., Liu, Z. and Zhou, Y. (2011) Anti-angiogenic and anti-inflammatory effects of SERPINA3K on corneal injury. PLoS ONE 6, e16712.
30. Stern, M. E. and Pflugfelder, S. C. (2004) Inflammation in dry eye. Ocul. Surf. 2, 124-130.
31. Lee, S. H., Kim, D. W., Eom, S. A., Jun, S. Y., Park, M., Kim, D. S., Kwon, H. J., Kwon, H. Y., Han, K. H., Park, J., Hwang, H. S., Eum, W. S. and Choi, S. Y. (2012) Suppression of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation in mice by transduced Tat-Annexin protein. BMB Rep. 45, 354-359.
32. Kubo, E., Fatma, N., Akagi, Y., Beier, D. R., Singh, S. P. and Singh, D. P. (2008) TAT-mediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity. Am. J. Physiol. Cell Physiol. 294, C842-C855.
33. Bradford, M. (1976) A rapid and sensitive method for the quantitation of microgram quantities utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248-254.
34. Suwan-apichon, O., Rizen, M., Rangsin, R., Herretes, S., Reyes, J. M., Lekhanont, K. and Chuck, R. S. (2006) Botulium toxin B-induced mouse model of keratoconjunctivitis sicca. Invest. Ophthalmol. Vis. Sci. 47, 133-139.
35. Lekhanont, K., Ilya, L., Suwan-apichon, O., Rangsin, R. and Chuck, R. S. (2007) Comparison of topical dry eye medications for the treatment of keratoconjunctivitis sicca in a botulium toxin B-induced mouse model. Cornea 26, 84-89.